A promising direction is the adjustment of HNSCC therapy based on dynamic changes occurring in the tumor microenvironment, including changes in the neutrophil-to-lymphocyte ratio, fluctuations in CRP values, and microsatellite instability. This evidence concerns the gene CRP and head and neck squamous cell carcinoma.